Senseonics Holdings, Inc. (SENS) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Senseonics is a medical technology company focused on implantable continuous glucose monitoring (CGM) systems, specifically the Eversense E3 and Eversense 365. A pivotal strategic shift occurred effective January 1, 2026, when the Company reassumed primary commercialization responsibilities in the United States from its former partner, Ascensia Diabetes Care Holdings AG, following the termination of Ascensia's exclusive U.S. rights. The Company is also transitioning commercial operations in select European territories (Italy, Germany, Spain, Sweden) from Ascensia, with closings expected by June 30, 2026.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $11,711 | $6,257 |
| Gross Profit | $6,940 | $1,505 |
| Gross Margin | 59.3% | 24.1% |
| Operating Loss | $(31,846) | $(13,488) |
| Net Loss | $(32,333) | $(14,259) |
| Net Loss Per Share (Basic & Diluted) | $(0.71) | $(0.40) |
| Cash, Cash Equivalents & Marketable Securities | $64,321 | $N/A |
| Long-Term Debt (Carrying Value) | $35,912 | $35,586 |
| Net Cash Used in Operating Activities | $(32,025) | $(16,080) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 87% year-over-year to $11.7 million. This was driven by a 416% increase in non-related party revenue ($9.3M vs $1.8M) due to the Company taking over U.S. commercialization and growth in the consignment program. Related party revenue (Ascensia) decreased 47% to $2.4M as U.S. rights were terminated.
- Margin Expansion: Gross margin improved significantly from 24.1% to 59.3%. This was attributed to favorable margins on the 365-day product, higher average selling prices (ASP) in the consignment network, and the elimination of revenue share payments to Ascensia for U.S. sales.
- Expense Surge: Selling, General, and Administrative (SG&A) expenses jumped 292% to $30.2 million. This increase is primarily due to the Company re-assuming commercialization activities, resulting in a significant headcount increase and higher direct-to-consumer marketing spend. R&D expenses increased 18% to $8.6 million, driven by the Gemini pivotal study.
- Going Concern Status: Management previously disclosed substantial doubt regarding the Company's ability to continue as a going concern. However, following recent financing activities (detailed below), management concluded that this doubt has been alleviated as of the filing date.
Guidance, Outlook, and Risks
- Recent Financing (Subsequent Events):
- Equity: On May 4, 2026, the Company completed an underwritten public offering raising approximately $92.0 million in gross proceeds (approx. $86.0 million net).
- Debt: On May 6, 2026, the Company amended its loan agreement with Hercules Capital, Inc., increasing the facility to $140.0 million. An additional $20.0 million was funded at closing.
- Outlook: The Company expects to continue investing heavily in commercialization and R&D. The transition of European commercial assets is expected to close by June 30, 2026. The Company is advancing the Gemini product (2-in-1 CGM/flash glucose) and Freedom product (Bluetooth-enabled sensor).
- Risks:
- Transition Risks: Delays in closing European asset purchases or disruptions in the transition from Ascensia could adversely affect operations.
- Debt Covenants: The amended loan agreement includes performance covenants based on net product revenue targets and minimum cash balances. Failure to meet these could result in default.
- Litigation: The Company is involved in patent infringement litigation with Cellspin Soft, Inc. Proceedings are currently stayed pending Inter Partes Review (IPR) outcomes.
Investor Verification Checklist
- Commercial Transition Execution: Verify the successful integration of the U.S. sales force and the timeline for closing European asset purchases (targeted June 30, 2026).
- Debt Covenant Compliance: Monitor the Company's ability to meet the new revenue targets and cash balance covenants under the amended Hercules Capital facility.
- Consignment Growth: Assess the sustainability of the revenue growth driven by the consignment model and direct-to-consumer marketing spend.
- Product Pipeline: Track progress on the Gemini pivotal study and regulatory approvals for the Freedom product.
- Litigation Status: Monitor the outcome of the Senseonics IPR proceedings regarding the Cellspin Soft patent infringement claims.